Comparison of a vasoconstrictor and a vasodilator in pharmacoangiography of bone and soft-tissue tumors.
The pharmacoangiographic effect of a vasoconstrictor (angiotensin) and a vasodilator (tolazoline) was compared in 18 patients with bone and soft-tissue tumors. Angiotensin was found to be the drug of choice in increasing diagnostic information on angiography. Ten to 15 mug of angiotensin seems to be a convenient dose in the axillary, iliac, and femoral arteries.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000792:Angiography; D000804:Angiotensin II / Q000494:pharmacology; D001859:Bone Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012039:Regional Blood Flow / Q000187:drug effects; D012983:Soft Tissue Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging*; D014043:Tolazoline / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology
D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D000804:Angiotensin II; D014043:Tolazoline